Ibex Medical Analytics has announced a research partnership and joint study with Institut Curie, France’s leading cancer centre, for the first-ever blinded and independent evaluation of an AI solution for breast cancer detection.
Already in use in select laboratories in Europe, Israel and the Americas, Ibex has developed the first artificial intelligence (AI)-based solution used in routine clinical practice for cancer diagnostics in pathology. This study aims to provide additional validation of Ibex’s technology for further usage in a top European healthcare centre.
There are over two million new cases of breast cancer worldwide every year, but, even with cancer prevalence increasing, it is still being diagnosed manually by pathologists using microscopes, which is both time-consuming and prone to human error. Add to that a decline in the number of pathologists, and the need for automated, more efficient diagnostic tools and methods is long overdue.
Log on to the Ibex website for more information.
